Emulating Hypothetical Target Trials of the Broad-Spectrum T2 Biologic Dupilumab
Overview
Overview
Authors
Authors
Affiliations
Affiliations
Soon will be listed here.
References
1.
Akenroye A, Segal J, Zhou G, Foer D, Li L, Alexander G
. Comparative effectiveness of omalizumab, mepolizumab, and dupilumab in asthma: A target trial emulation. J Allergy Clin Immunol. 2023; 151(5):1269-1276.
PMC: 10164684.
DOI: 10.1016/j.jaci.2023.01.020.
View
2.
Nopsopon T, Lassiter G, Chen M, Alexander G, Keet C, Hong H
. Comparative efficacy of tezepelumab to mepolizumab, benralizumab, and dupilumab in eosinophilic asthma: A Bayesian network meta-analysis. J Allergy Clin Immunol. 2022; 151(3):747-755.
PMC: 9992307.
DOI: 10.1016/j.jaci.2022.11.021.
View
3.
Akenroye A, Lassiter G, Jackson J, Keet C, Segal J, Alexander G
. Comparative efficacy of mepolizumab, benralizumab, and dupilumab in eosinophilic asthma: A Bayesian network meta-analysis. J Allergy Clin Immunol. 2022; 150(5):1097-1105.e12.
PMC: 9643621.
DOI: 10.1016/j.jaci.2022.05.024.
View
4.
Kearney C, Sangani R, Shankar D, OConnor G, Law A, Walkey A
. Comparative Effectiveness of Mepolizumab, Benralizumab, and Dupilumab among Patients with Difficult-to-Control Asthma: A Multicenter Retrospective Propensity-matched Analysis. Ann Am Thorac Soc. 2024; 21(6):866-874.
PMC: 11160126.
DOI: 10.1513/AnnalsATS.202306-566OC.
View
5.
Hernan M
. Methods of Public Health Research - Strengthening Causal Inference from Observational Data. N Engl J Med. 2021; 385(15):1345-1348.
DOI: 10.1056/NEJMp2113319.
View